Recovery

### Recovery (essai clinique)

L'essai démarre en avril 2020, avec initialement la participation de 132 hôpitaux au Royaume-Uni1, puis s'étend pour devenir le plus large essai au monde de traitement de la COVID‑19, impliquant 5400 personnes infectées dans 165 hôpitaux le 17 avril 2020.

Le 5 juin, les responsables de l'essai concluent que le traitement par l'hydroxychloroquine n'est pas un traitement efficace pour les patients hospitalisés atteints de Covid-19, et décident de stopper cette branche de l'essai. Martin Landray déclare que ces résultats préliminaires devraient « changer les pratiques médicales à travers le monde »

Selon un rapport publié le 16 juin, la dexaméthasone réduit d’un tiers la mortalité chez les patients les plus atteints par la Covid-197. C'est le premier médicament dont un vaste essai clinique randomisé montre qu’il améliore la survie des patients gravement atteints8.

23/03/2020

https://www.recoverytrial.net/news/oxfords-covid-19-research-receives-government-funding

Lopinavir-Ritonavir, commonly used to treat HIV;

END 05/10/2020 : https://www.recoverytrial.net/news/lopinavir-ritonavir-is-not-an-effective-treatment-for-patients-hospitalised-with-covid-19

23/03/2020

https://www.recoverytrial.net/news/oxfords-covid-19-research-receives-government-funding

Low-dose corticosteroids <- Dexamethasone

3 April 2020

https://www.recoverytrial.net/news/update

Dexamethasone, a type of steroid use in a range of conditions to reduce inflammation

OK 16/06/2020 : https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19

03/04/2020

https://www.recoverytrial.net/news/update

Hydroxychloroquine, a treatment for malaria.

END 05/06/2020 : https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19

14/04/2020

2020-04-14--recovery--protocol-v4-0

Azithromycin

END 14/12/2020 : https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19

14/04/2020

2020-04-14--recovery--protocol-v4-0

Tocilizumab

OK 11/02/2021 : https://www.recoverytrial.net/news/tocilizumab-reduces-deaths-in-patients-hospitalised-with-covid-19

03/06/2020

https://www.recoverytrial.net/news/first-patient-a-child-receives-convalescent-plasma-through-recovery-the-dedicated-covid-19-

Convalescent Plasma

END 15/01/2021 : 2021-01-15--recovery--closes recruitment to convalescent plasma.pdf

14/09/2020

https://www.recoverytrial.net/news/recovery-covid-19-phase-3-trial-to-evaluate-regeneron2019s-regn-cov2-investigational-antibody-cocktail-in-the-uk

Regeneron

EN COURS

06/11/2020

https://www.recoverytrial.net/news/aspirin-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial

Aspirin

EN COURS

27/11/2020

https://www.recoverytrial.net/news/colchicine-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial

Colchicine

END 05/03/2021 : https://www.recoverytrial.net/news/recovery-trial-closes-recruitment-to-colchicine-treatment-for-patients-hospitalised-with-covid-19

02/02/2021

https://www.recoverytrial.net/news/baricitinib-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial

Baricitinib

EN COURS

05/06/2020

https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19

hydroxy stop

Aspirin

https://www.recoverytrial.net/results/aspirin-results

https://www.recoverytrial.net/news/aspirin-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial

début 6 nov 2020

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

Azithromycin

https://www.recoverytrial.net/results/azithromycin-results

https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19

2020.12.10

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

Colchicine

https://www.recoverytrial.net/results/colchicine

05 mars 2021

There has been no convincing evidence of the effect of colchicine

Convalescent Plasma

https://www.recoverytrial.net/results/convalescent-plasma

treatment-trial

15/01/2021

There has been no convincing evidence of the effect of convalescent plasma

Dexamethasone

https://www.recoverytrial.net/results/dexamethasone-results

https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19

16/06/2020

Low-cost dexamethasone reduces death by up to one third

Hydroxychloroquine

https://www.recoverytrial.net/results/hydroxychloroquine-results

https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19

05/06/2020

no clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19

Lopinavir-Ritonavir

https://www.recoverytrial.net/news/lopinavir-ritonavir-is-not-an-effective-treatment-for-patients-hospitalised-with-covid-19

https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery

Study Protocol

Tocilizumab

https://www.recoverytrial.net/results/tocilizumab-results

https://www.recoverytrial.net/news/tocilizumab-reduces-deaths-in-patients-hospitalised-with-covid-19